These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37019745)
61. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis. Mahlen T; Barton L; Roberts D J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048 [TBL] [Abstract][Full Text] [Related]
62. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. Douglas JE; Civantos AM; Locke TB; Sweis AM; Hadjiliadis D; Hong G; Dorgan DJ; Kohanski MA; Palmer JN; Adappa ND Int Forum Allergy Rhinol; 2021 Feb; 11(2):201-203. PubMed ID: 33070454 [No Abstract] [Full Text] [Related]
63. Discovery heralds new approach to the treatment of cystic fibrosis. Lowe JA J Med Chem; 2014 Dec; 57(23):9774-5. PubMed ID: 25384240 [No Abstract] [Full Text] [Related]
64. After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy. Barry PJ; Jones AM Ann Am Thorac Soc; 2019 Feb; 16(2):189-190. PubMed ID: 30707058 [No Abstract] [Full Text] [Related]
65. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Lahiri T; Sullivan JS Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419 [TBL] [Abstract][Full Text] [Related]
66. A new era in the treatment of cystic fibrosis. Lane MA; Doe SJ Clin Med (Lond); 2014 Feb; 14(1):76-8. PubMed ID: 24532752 [No Abstract] [Full Text] [Related]
67. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
76. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
77. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Middleton PG; Taylor-Cousar JL Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928 [No Abstract] [Full Text] [Related]
78. Promising new era dawns for cystic fibrosis treatment. Corbyn Z Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244 [No Abstract] [Full Text] [Related]
79. The march towards CFTR modulator access for all people with CF: The end of the beginning. VanDevanter DR J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080 [No Abstract] [Full Text] [Related]
80. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE; Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]